Back to Agenda
S25 : Exploring Exit Strategies and Challenges for dBM Development in Pharmaceutical Drug Development
Session Chair(s)
Yoshihiko Furusawa, MD, PhD
Head of Rare Diseases, Medical Franchise, Japan Medical Office
Takeda Pharmaceutical Company Limited, Japan
Speaker(s)
NORIHIRO KAWABATA
Chugai Pharmaceutical Co., Ltd., Japan
Specialty Clinical Research Dept. Clinical Science Professional
Kazumichi Minato
Techdoctor, Inc., Japan
CEO
Steve Xu, MD, MSc
Northwestern University, United States
Medical Director
Tomoharu DOHI
Pharmaceuticals and Medical Devices Agency, Japan
Have an account?